Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2010

View Archived Issues

Multiple Survival Screening: A new algorithm to predict low-risk breast cancer

Clinical data presented on DiaPep-277 in type 1 diabetes

Scientists describe CFTR inhibitors for acute secretory diarrhea

VP-20621 generally well tolerated in phase I study

ARRY-502 well tolerated in phase I study

Prucalopride enters phase III trial in men with chronic constipation

Johnson & Johnson acquires Micrus Endovascular

Sanofi Pasteur to acquire VaxDesign

FDA approves Cobas AmpliPrep/Cobas TaqMan HBV test v2.0

Dana-Farber Cancer Institute and sanofi-aventis collaborate on oncology targets

New phase II OGX-427 trial begins in metastatic prostate cancer

CONQUER trial reveals benefits of phentermine/topiramate combination in obesity

GSK patents new voltage-gated Ca(V)2.2 calcium channel ligands

Amira Pharma files IND application with FDA for AM-152

KAI-4169 enters phase Ib trial for secondary hyperparathyroidism in ESRD

Pfizer discontinues phase III Sutent trial in castration-resistant prostate cancer

Galapagos starts phase II trial of GLPG-0259 in rheumatoid arthritis

Elixir Pharmaceuticals claims new ghrelin receptor modulators

Seroquel XL approved in U.K. as add-on therapy for major depressive disorder

Genta initiates new phase II trial of tesetaxel in advanced bladder cancer

UC claims new modulators of nAChR subunit alpha7 and GABA(A) receptors

Organon synthesizes novel serotonin 5-HT2C receptor modulators

Homopiperazine acethydrazide derivatives patented as oncolytic agents

Nippon Zoki discloses new histidine derivatives

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.